Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Return on Capital Employed (2016 - 2025)

Cytokinetics (CYTK) has disclosed Return on Capital Employed for 14 consecutive years, with 0.52% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed changed N/A to 0.52% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.52%, a N/A change, with the full-year FY2023 number at 0.61%, down 22.0% from a year prior.
  • Return on Capital Employed was 0.52% for Q4 2025 at Cytokinetics, down from 0.46% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.2% in Q1 2021 to a low of 0.73% in Q4 2023.
  • A 5-year average of 0.42% and a median of 0.38% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -47bps in 2023, then surged 34bps in 2024.
  • Cytokinetics' Return on Capital Employed stood at 0.24% in 2021, then tumbled by -38bps to 0.34% in 2022, then tumbled by -116bps to 0.73% in 2023, then surged by 48bps to 0.38% in 2024, then crashed by -36bps to 0.52% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Return on Capital Employed are 0.52% (Q4 2025), 0.46% (Q1 2025), and 0.38% (Q3 2024).